Cara Therapeutics Inc.

Cara Therapeutics Inc. is a biopharmaceutical company dedicated to developing and commercializing new chemical entities designed to alleviate pain and pruritus, also known as itch. The company's primary focus is on treatments targeting the kappa opioid receptor, which differs from traditional pain management approaches that often rely on the mu opioid receptor, thereby reducing the risk of addiction and abuse. Cara's research and development emphasize innovating prescription pharmaceuticals for serious medical conditions, predominantly within the realm of dermatological and renal care. The company's flagship product, Korsuva, is approved for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis. Cara Therapeutics plays a crucial role in addressing unmet medical needs, particularly in chronic kidney disease, where patients frequently experience complex and debilitating symptoms. By continuing to advance its product pipeline, Cara Therapeutics positions itself as a significant player in the biopharmaceutical sector, fostering advancements in patient care and contributing to the evolving landscape of pain management and anti-itch therapies within the healthcare industry.